Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
TK Teekay Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Price
Delayed
$124.67
Day's Change
0.055 (0.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.49
Day's Low
121.22
Volume
(Light)

Today's volume of 22,044 shares is on pace to be much lighter than KRTX's 10-day average volume of 191,081 shares.

22,044

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against SelectQuote, Inc. (SLQT)

12:15 pm ET October 13, 2021 (BusinessWire) Print

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 15, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased SelectQuote, Inc. ("SelectQuote" or "the Company") (NYSE: SLQT) securities between February 8, 2021 and May 11, 2021, inclusive (the "Class Period").

If you are a shareholder who suffered a loss, click here to participate.

On May 11, 2021, SelectQuote held a conference call in connection with its third quarter 2021 financial results during which it disclosed that its fourth quarter results would be impacted by a "negative cohort and tail adjustment" due to "lower second-term persistency for the 2019 cohort."

On this news, the Company's share price fell $5.50, or 20%, to close at $21.90 per share on May 12, 2021, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made material misrepresentations concerning the following: (1) that SelectQuote's 2019 cohort was underperforming; (2) that, as a result, the Company's financial results would be adversely impacted; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased or otherwise acquired SelectQuote securities during the Class Period, you may move the Court no later than October 15, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005016/en/

SOURCE: The Law Offices of Frank R. Cruz">

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com 
www.frankcruzlaw.com
comtex tracking

COMTEX_395115897/1006/2021-10-13T12:15:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.